
Harmony Biosciences Holdings (HRMY) just released third quarter results, pairing slightly softer quarterly earnings with higher year to date profit and a reaffirmed full year revenue outlook between US$1.0b and US$1.04b.
Harmony Biosciences Holdings’ recent earnings update lands after a choppy stretch for the stock, with the share price down about 11% over the past month and 90 days, and around 10% lower year to date. At the same time, the 3 year total shareholder return is positive at roughly 25%. This mix of softer recent share price performance and a largely flat 1 year total shareholder return, near 1% lower, suggests momentum has cooled in the short term, while investors are still weighing the longer run potential pay off from the rare disease portfolio and reaffirmed revenue guidance around US$1.0b to US$1.04b.
Look beyond Harmony Biosciences Holdings and consider lining up other rarer, resilient opportunities with our curated list of 30 resilient stocks with low risk scores as earnings stories like this one continue to be repriced.
After Harmony Biosciences Holdings’ muted share move against firmer year to date profit and confirmed revenue guidance, the real puzzle now is whether most of the rerating has already happened or if meaningful upside still sits ahead on valuation.
Harmony Biosciences Holdings closed at $33.76 against a fair value estimate of $47.64 in the analyst consensus Narrative on Simply Wall St, which is built from analyst earnings and revenue forecasts as well as their price targets, using a 7.24% discount rate to pull those expectations back into today’s terms.
Use of Harmony Biosciences Holdings' cash position of about US$962.5 million against US$155 million of debt, together with ongoing profitability, provides capacity to fund R&D and business development transactions aimed at products with 2028 to 2032 launch windows, which can support post 2030 revenue and earnings. Execution on an intellectual property and litigation program that includes a multilayered pitolisant patent estate, settlements with most generic filers and new amorphous pitolisant rights, supports WAKIX market exclusivity into March 2030 and potentially longer through next generation formulations, which can help sustain revenue and cash flow while pipeline assets mature.
See why 108 investors see Harmony Biosciences Holdings as 29% undervalued.
Result: Fair Value of $47.64 (UNDERVALUED)
Still, Harmony Biosciences Holdings faces two clear pressure points: heavy dependence on WAKIX for revenue and the risk that higher royalties squeeze future profitability.
Find out about the key risks to this Harmony Biosciences Holdings narrative.
Curious whether the mood around Harmony Biosciences Holdings matches your own read of the numbers and risks? Take a closer look at the upside case through the 3 key rewards.
If Harmony Biosciences Holdings has your attention, do not stop here. Fresh opportunities sit just a few clicks away, and other investors are already hunting.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com